ISOTRETINOIN (isotretinoin) by Viatris (2) is retinoid, which when administered at the recommended dosage [see dosage and administration ()], inhibits sebaceous gland function and keratinization. Approved for severe recalcitrant nodular acne in non-pregnant patients 12 years of age, older with multiple inflammatory nodules with a diameter of 5 mm, greater. First approved in 2025.
Drug data last refreshed 18h ago
retinoid, which when administered at the recommended dosage [see Dosage and Administration ()], inhibits sebaceous gland function and keratinization. Clinical improvement in nodular acne patients occurs in association with a reduction in sebum secretion. The decrease in sebum secretion is temporary…
Retinoid
Worked on ISOTRETINOIN at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Efficacy of Cosmetic Product RV3278B-OS0386 in the Maintenance Phase After Oral Isotretinoin Treatment of Adults Subjects With Facial Acne.
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)
The Effect of Isotretinoin on the Etonogestrel Contraceptive Implant